At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 917 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Phase 3, Open-label Trial Comparing the Effect of Tirzepatide Once Weekly Versus Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Metformin With or Without a Sulfonylurea
In Brief
A Phase 3 clinical trial evaluating Tirzepatide and Insulin Glargine for Type 2 Diabetes. Completed, enrolled 917 participants across 67 sites in 4 countries.
Detailed Summary
The main reason for this study is to compare the study drug tirzepatide to insulin glargine in participants with type 2 diabetes on metformin with or without a sulfonylurea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesAustralia, China, India, South Korea
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartDec 2019
Primary CompletionNov 2021
Study CompletionNov 2021
TodayJul 2026
First PostedSep 18, 2019
Enrollment StartDec 9, 2019
Primary CompletionNov 1, 2021
Study CompletionNov 24, 2021
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.8 years ago
Interventions
Tirzepatidedrug
Administered SC
Insulin Glarginedrug
Administered SC